- 10/25/2023 4:49:03 PM | 訪問量:1748
抗腫瘤藥物體外模型

- 上一篇:大鼠心肌缺血模型
- 下一篇:Balb/c-Nu小鼠原位肝癌模型
- 天勤生物聯合多家企業榮獲湖北省科學技術進步二等獎
- 2025-09-03
近(jin)日,2025年度(du)湖(hu)(hu)北(bei)(bei)省科學技(ji)術(shu)(shu)進(jin)步(bu)獎(jiang)名單公示,由天勤生(sheng)物聯(lian)合湖(hu)(hu)北(bei)(bei)省醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)工業(ye)研(yan)究(jiu)(jiu)院有限(xian)公司(si)、湖(hu)(hu)北(bei)(bei)麗益醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)科技(ji)有限(xian)公司(si)、湖(hu)(hu)北(bei)(bei)科益藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)業(ye)股份有限(xian)公司(si)、武漢福(fu)星生(sheng)物藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)業(ye)有限(xian)公司(si)共同(tong)完成(cheng)(cheng)(cheng)的“湖(hu)(hu)北(bei)(bei)道地與(yu)特色藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)用(yong)(yong)(yong)(yong)價(jia)值(zhi)的深(shen)(shen)度(du)挖掘及其應(ying)(ying)用(yong)(yong)(yong)(yong)”項(xiang)(xiang)(xiang)目(mu),榮(rong)獲二(er)等(deng)獎(jiang)。這一成(cheng)(cheng)(cheng)果標志著(zhu)湖(hu)(hu)北(bei)(bei)省在(zai)道地藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)資(zi)(zi)源(yuan)開(kai)(kai)發(fa)利用(yong)(yong)(yong)(yong)與(yu)中(zhong)(zhong)醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)現代(dai)(dai)(dai)化(hua)(hua)研(yan)究(jiu)(jiu)方(fang)面取得重(zhong)要進(jin)展。 該項(xiang)(xiang)(xiang)目(mu)系統針對湖(hu)(hu)北(bei)(bei)省道地藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)及特色藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)用(yong)(yong)(yong)(yong)資(zi)(zi)源(yuan),在(zai)活性(xing)(xing)成(cheng)(cheng)(cheng)分(fen)提(ti)取、藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)理(li)(li)機制探索以(yi)及現代(dai)(dai)(dai)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)物研(yan)發(fa)等(deng)方(fang)面,開(kai)(kai)展從基礎研(yan)究(jiu)(jiu)到產(chan)業(ye)應(ying)(ying)用(yong)(yong)(yong)(yong)的全鏈條協同(tong)攻關。湖(hu)(hu)北(bei)(bei)省作為中(zhong)(zhong)醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)資(zi)(zi)源(yuan)大省,素有“華中(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)庫”之(zhi)美譽(yu),但藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)資(zi)(zi)源(yuan)的深(shen)(shen)度(du)開(kai)(kai)發(fa)和現代(dai)(dai)(dai)化(hua)(hua)應(ying)(ying)用(yong)(yong)(yong)(yong)仍面臨一定(ding)的局限(xian)。該項(xiang)(xiang)(xiang)目(mu)不僅(jin)提(ti)升了湖(hu)(hu)北(bei)(bei)道地藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)的應(ying)(ying)用(yong)(yong)(yong)(yong)水平,也為區域(yu)性(xing)(xing)中(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)產(chan)業(ye)提(ti)質(zhi)(zhi)增效和結構升級提(ti)供了技(ji)術(shu)(shu)支撐。天勤生(sheng)物作為項(xiang)(xiang)(xiang)目(mu)參與(yu)方(fang)之(zhi)一,在(zai)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)物藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)理(li)(li)與(yu)毒理(li)(li)研(yan)究(jiu)(jiu)、成(cheng)(cheng)(cheng)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)性(xing)(xing)評價(jia)等(deng)領域(yu)發(fa)揮(hui)了重(zhong)要作用(yong)(yong)(yong)(yong)。 這一獎(jiang)項(xiang)(xiang)(xiang)的獲得,不僅(jin)是對項(xiang)(xiang)(xiang)目(mu)組創新(xin)實踐的高度(du)認可(ke),更將進(jin)一步(bu)推動湖(hu)(hu)北(bei)(bei)省中(zhong)(zhong)醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)資(zi)(zi)源(yuan)的系統性(xing)(xing)挖掘與(yu)價(jia)值(zhi)轉化(hua)(hua)。未來,相關技(ji)術(shu)(shu)成(cheng)(cheng)(cheng)果有望(wang)在(zai)更多(duo)道地藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)材(cai)(cai)(cai)研(yan)究(jiu)(jiu)中(zhong)(zhong)推廣應(ying)(ying)用(yong)(yong)(yong)(yong),為中(zhong)(zhong)醫(yi)(yi)(yi)藥(yao)(yao)(yao)(yao)(yao)(yao)(yao)(yao)現代(dai)(dai)(dai)化(hua)(hua)和產(chan)業(ye)高質(zhi)(zhi)量發(fa)展持續注入新(xin)動能(neng)。
- 天勤生物助力人福醫藥IPF新藥HW241045片獲批臨床
- 2025-08-12
近日,國(guo)家藥(yao)品監督(du)(du)管(guan)(guan)理(li)(li)局藥(yao)品審評(ping)中心(xin)(CDE)官(guan)網公示,人(ren)福(fu)醫(yi)藥(yao)集團申報的(de)(de)(de)(de)(de)(de)1類(lei)創新(xin)藥(yao)HW241045片正(zheng)式獲得(de)國(guo)家藥(yao)品監督(du)(du)管(guan)(guan)理(li)(li)局頒發(fa)(fa)的(de)(de)(de)(de)(de)(de)《藥(yao)物(wu)(wu)(wu)臨床(chuang)試(shi)驗(yan)批準通(tong)(tong)知書》,擬用于治療特(te)發(fa)(fa)性肺纖維化(hua)(IPF)。在這一重大進(jin)(jin)展(zhan)背后,天(tian)勤(qin)生(sheng)物(wu)(wu)(wu)提供的(de)(de)(de)(de)(de)(de)全方(fang)位毒理(li)(li)學(xue)研(yan)(yan)究支持,為(wei)(wei)該項目獲批按下(xia)"加速鍵"。聚焦未滿(man)足臨床(chuang)需求(qiu),HW241045片引(yin)領呼吸(xi)領域(yu)創新(xin)突破HW241045片作為(wei)(wei)人(ren)福(fu)醫(yi)藥(yao)重點布局的(de)(de)(de)(de)(de)(de)1類(lei)創新(xin)藥(yao),聚焦臨床(chuang)需求(qiu)迫切的(de)(de)(de)(de)(de)(de)IPF領域(yu)。IPF作為(wei)(wei)一種進(jin)(jin)行(xing)性肺部疾病(bing),患者預后差,現有治療選擇有限。HW241045片的(de)(de)(de)(de)(de)(de)研(yan)(yan)發(fa)(fa)進(jin)(jin)展(zhan),為(wei)(wei)患者帶(dai)來了新(xin)的(de)(de)(de)(de)(de)(de)希望曙光(guang)。科學(xue)把控(kong),天(tian)勤(qin)生(sheng)物(wu)(wu)(wu)毒理(li)(li)研(yan)(yan)究助力(li)HW241045片加速獲批針對(dui)HW241045片的(de)(de)(de)(de)(de)(de)非臨床(chuang)毒理(li)(li)研(yan)(yan)究,天(tian)勤(qin)生(sheng)物(wu)(wu)(wu)展(zhan)現了成熟(shu)的(de)(de)(de)(de)(de)(de)試(shi)驗(yan)設計(ji)與執(zhi)行(xing)能力(li)。從(cong)試(shi)驗(yan)方(fang)案的(de)(de)(de)(de)(de)(de)科學(xue)論證(zheng)到試(shi)驗(yan)過程的(de)(de)(de)(de)(de)(de)精細(xi)化(hua)管(guan)(guan)理(li)(li),團隊通(tong)(tong)過標準化(hua)操作流程和動態風險評(ping)估機制(zhi),有效確保了數據可靠性與合規性。其(qi)對(dui)項目節奏的(de)(de)(de)(de)(de)(de)科學(xue)化(hua)把控(kong)也為(wei)(wei)人(ren)福(fu)醫(yi)藥(yao)搶抓臨床(chuang)申報提供了關(guan)鍵支持,保障了該項目順利(li)通(tong)(tong)過審評(ping)。此次與人(ren)福(fu)醫(yi)藥(yao)的(de)(de)(de)(de)(de)(de)成功合作,也印證(zheng)了天(tian)勤(qin)生(sheng)物(wu)(wu)(wu)作的(de)(de)(de)(de)(de)(de)專業價值。其(qi)系統化(hua)的(de)(de)(de)(de)(de)(de)技術平臺(tai)與嚴(yan)謹(jin)高效的(de)(de)(de)(de)(de)(de)研(yan)(yan)究服務,正(zheng)日益成為(wei)(wei)本土創新(xin)藥(yao)企加...
- 天勤生物攜手睿智醫藥,共筑從靶點到IND一站式新藥研發平臺
- 2025-07-29
近日,天勤(qin)(qin)生(sheng)(sheng)物與(yu)睿(rui)智醫(yi)藥(yao)(yao)(yao)科技股份(fen)有(you)(you)限(xian)公司(以(yi)下稱“睿(rui)智醫(yi)藥(yao)(yao)(yao)”)正式(shi)簽(qian)署戰略合作(zuo)(zuo)(zuo)(zuo)協議。此次合作(zuo)(zuo)(zuo)(zuo)旨在(zai)(zai)(zai)深度融合雙(shuang)方(fang)(fang)在(zai)(zai)(zai)創新(xin)藥(yao)(yao)(yao)研(yan)發(fa)(fa)產(chan)(chan)業鏈上的(de)(de)核心優(you)(you)勢,共同(tong)打造(zao)覆(fu)蓋“從(cong)靶(ba)點發(fa)(fa)現至(zhi)IND”全流程的(de)(de)一站式(shi)服(fu)務平(ping)臺(tai),為全球藥(yao)(yao)(yao)企提(ti)供更高(gao)效(xiao)、更專業的(de)(de)解(jie)決方(fang)(fang)案。 睿(rui)智醫(yi)藥(yao)(yao)(yao)作(zuo)(zuo)(zuo)(zuo)為國(guo)內(nei)臨床前CRO領(ling)域(yu)的(de)(de)佼(jiao)佼(jiao)者(zhe),自2004年成立以(yi)來,已構建起從(cong)抗體及化藥(yao)(yao)(yao)早期研(yan)發(fa)(fa)、藥(yao)(yao)(yao)理(li)藥(yao)(yao)(yao)效(xiao)、藥(yao)(yao)(yao)代動(dong)力(li)學到早期毒(du)理(li)研(yan)究(jiu)、生(sheng)(sheng)物分(fen)析乃(nai)至(zhi)生(sheng)(sheng)物藥(yao)(yao)(yao)工藝開(kai)發(fa)(fa)與(yu)生(sheng)(sheng)產(chan)(chan)的(de)(de)全鏈條(tiao)能(neng)力(li),尤其在(zai)(zai)(zai)靶(ba)點驗(yan)證到IND申報的(de)(de)早期創新(xin)階段具備強大(da)(da)(da)實力(li)。 天勤(qin)(qin)生(sheng)(sheng)物在(zai)(zai)(zai)創新(xin)藥(yao)(yao)(yao)物臨床前安全性(xing)評價(jia)領(ling)域(yu)擁(yong)有(you)(you)深厚(hou)積累,特別是在(zai)(zai)(zai)大(da)(da)(da)分(fen)子治療(liao)性(xing)藥(yao)(yao)(yao)物、細胞與(yu)基(ji)因治療(liao)產(chan)(chan)品等領(ling)域(yu)的(de)(de)研(yan)究(jiu)有(you)(you)獨特優(you)(you)勢,在(zai)(zai)(zai)非人靈長類動(dong)物模型構建與(yu)藥(yao)(yao)(yao)效(xiao)評價(jia)及猴生(sheng)(sheng)殖與(yu)發(fa)(fa)育毒(du)性(xing)方(fang)(fang)面(mian)也能(neng)力(li)突出,其服(fu)務全面(mian)覆(fu)蓋藥(yao)(yao)(yao)物毒(du)理(li)安全性(xing)評價(jia)、藥(yao)(yao)(yao)代藥(yao)(yao)(yao)效(xiao)研(yan)究(jiu)、生(sheng)(sheng)物分(fen)析及大(da)(da)(da)動(dong)物模型開(kai)發(fa)(fa)等關鍵環(huan)節。 此次合作(zuo)(zuo)(zuo)(zuo),天勤(qin)(qin)生(sheng)(sheng)物和睿(rui)智醫(yi)藥(yao)(yao)(yao)將精(jing)準契(qi)合創新(xin)藥(yao)(yao)(yao)研(yan)發(fa)(fa)產(chan)(chan)業鏈的(de)(de)各自優(you)(you)勢環(huan)節,形成資源互補、聯合攻關的(de)(de)強大(da)(da)(da)合力(li),并在(zai)(zai)(zai)此基(ji)礎(chu)上緊密協作(zuo)(zuo)(zuo)(zuo),共同(tong)組(zu)建“從(cong)靶(ba)點到IND的(de)(de)一站式(shi)新(xin)藥(yao)(yao)(yao)研(yan)發(fa)(fa)平(ping)臺(tai)”。該平(ping)臺(tai)將致力(li)于為客戶提(ti)供更全面(mian)、更具創...
- 天勤生物榮膺CGT領域最佳CRO合作伙伴啟明星獎
- 2025-06-09
在(zai)第六屆國際細(xi)胞與基因治療(liao)中國峰會(hui)暨展覽(lan)會(hui)(CGCS 2025)現(xian)場,備受矚(zhu)目的(de)(de)CGCS Awards啟明(ming)星(xing)獎(jiang)(jiang)項隆重揭曉。天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)憑(ping)借其(qi)在(zai)細(xi)胞與基因治療(liao)(CGT)非臨床(chuang)研(yan)究(jiu)領域(yu)的(de)(de)突出貢獻,從(cong)眾多競爭者(zhe)中脫穎(ying)而出,榮(rong)(rong)膺 “CGT領域(yu)最佳CRO合(he)作伙(huo)伴(ban)啟明(ming)星(xing)獎(jiang)(jiang)”。這一(yi)殊榮(rong)(rong)是(shi)CGCS組(zu)委(wei)會(hui)及行業權威(wei)專(zhuan)家對(dui)(dui)天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)在(zai)該(gai)領域(yu)核心(xin)(xin)價值的(de)(de)高(gao)度(du)(du)肯定(ding)。 CGCS Awards啟明(ming)星(xing)獎(jiang)(jiang)評(ping)選(xuan)活動由CGCS組(zu)委(wei)會(hui)權威(wei)發起,評(ping)選(xuan)過程嚴(yan)謹公正,融合(he)了(le)組(zu)委(wei)會(hui)資深(shen)(shen)專(zhuan)家評(ping)審團的(de)(de)深(shen)(shen)度(du)(du)評(ping)議(yi)與廣(guang)泛網絡投票。評(ping)審維度(du)(du)覆蓋(gai)技(ji)(ji)術實(shi)用性(xing)與創(chuang)新(xin)性(xing)、市場表現(xian)、客戶服務口碑、未來(lai)發展潛力等多個核心(xin)(xin)指(zhi)標。天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)以(yi)其(qi)深(shen)(shen)厚的(de)(de)技(ji)(ji)術積累、可靠的(de)(de)服務質量以(yi)及來(lai)自合(he)作伙(huo)伴(ban)的(de)(de)廣(guang)泛贊譽,在(zai)綜合(he)評(ping)選(xuan)中實(shi)力勝(sheng)出。 此(ci)次獲獎(jiang)(jiang),不僅(jin)彰(zhang)顯(xian)了(le)天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)在(zai)CGT非臨床(chuang)研(yan)究(jiu)服務鏈條(tiao)中作為關鍵支(zhi)撐者(zhe)與可信賴伙(huo)伴(ban)的(de)(de)核心(xin)(xin)地位,更(geng)是(shi)業界對(dui)(dui)其(qi)賦(fu)能創(chuang)新(xin)療(liao)法安全高(gao)效開發所發揮作用的(de)(de)廣(guang)泛認可。天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)始終致力于打(da)造專(zhuan)業高(gao)效的(de)(de)CRO服務平臺(tai),其(qi)科學嚴(yan)謹的(de)(de)研(yan)究(jiu)體(ti)系與解決方案,已(yi)成為加速(su)CGT產品從(cong)實(shi)驗室走向(xiang)臨床(chuang)、惠及患者(zhe)的(de)(de)重要保障。 天(tian)(tian)勤(qin)(qin)生(sheng)(sheng)物(wu)將繼續深(shen)(shen)化在(zai)CG...
- 天勤生物受邀出席同濟醫院綜合類國家醫學中心科創院理事會成立大會
- 2025-06-05
6月(yue)4日上(shang)午,同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)綜(zong)合(he)類國家(jia)(jia)醫(yi)(yi)(yi)學(xue)中心(籌)科(ke)(ke)創(chuang)(chuang)院(yuan)(yuan)(yuan)(yuan)(yuan)理(li)事會(hui)成立大會(hui)在武漢同(tong)(tong)(tong)濟(ji)產業(ye)科(ke)(ke)創(chuang)(chuang)中心隆重(zhong)舉行(xing)。作(zuo)為(wei)同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)重(zhong)要的(de)(de)(de)戰(zhan)略合(he)作(zuo)伙伴,天勤生(sheng)物(wu)受邀出(chu)席(xi)盛會(hui),與(yu)各界(jie)代表共(gong)繪醫(yi)(yi)(yi)學(xue)創(chuang)(chuang)新(xin)藍圖(tu)。 本次(ci)大會(hui)規格(ge)隆重(zhong),由(you)同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)常務(wu)副(fu)(fu)院(yuan)(yuan)(yuan)(yuan)(yuan)長、科(ke)(ke)創(chuang)(chuang)院(yuan)(yuan)(yuan)(yuan)(yuan)理(li)事會(hui)常務(wu)副(fu)(fu)理(li)事長廖家(jia)(jia)智主持。湖北省、武漢市及硚口區相關(guan)部門(men)領導(dao),同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)及科(ke)(ke)創(chuang)(chuang)院(yuan)(yuan)(yuan)(yuan)(yuan)負(fu)責人(ren)(ren),中國工程院(yuan)(yuan)(yuan)(yuan)(yuan)院(yuan)(yuan)(yuan)(yuan)(yuan)士馬(ma)丁(ding)等(deng)領導(dao)專家(jia)(jia)出(chu)席(xi)。來(lai)自40家(jia)(jia)國內外頂尖醫(yi)(yi)(yi)療企業(ye)的(de)(de)(de)百(bai)余名(ming)代表參會(hui),共(gong)同(tong)(tong)(tong)見證。 天勤生(sheng)物(wu)作(zuo)為(wei)與(yu)會(hui)方,其與(yu)同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)的(de)(de)(de)戰(zhan)略合(he)作(zuo),正是響(xiang)應大會(hui)倡導(dao)的(de)(de)(de)“產學(xue)研(yan)(yan)深(shen)度融合(he)”方向。雙(shuang)方致力于整合(he)同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)在科(ke)(ke)技研(yan)(yan)發、高(gao)端人(ren)(ren)才資源與(yu)卓越醫(yi)(yi)(yi)學(xue)教育方面的(de)(de)(de)深(shen)厚積淀(dian),以(yi)及天勤生(sheng)物(wu)在非人(ren)(ren)靈長類實驗(yan)動物(wu)模型開發、高(gao)標準新(xin)藥非臨(lin)(lin)床(chuang)研(yan)(yan)究服務(wu)、先進大動物(wu)分子影像檢測(ce)平臺等(deng)領域(yu)(yu)的(de)(de)(de)核心優(you)勢。此次(ci)合(he)作(zuo)以(yi)具體(ti)項目為(wei)紐(niu)帶,旨在構(gou)建(jian)“產學(xue)研(yan)(yan)用”一體(ti)化(hua)(hua)創(chuang)(chuang)新(xin)鏈條,加速科(ke)(ke)研(yan)(yan)成果(guo)向臨(lin)(lin)床(chuang)治(zhi)療應用的(de)(de)(de)轉化(hua)(hua)進程,最終(zhong)惠(hui)及人(ren)(ren)民健康(kang)福祉,實現優(you)勢互(hu)補、互(hu)惠(hui)雙(shuang)贏。 天勤生(sheng)物(wu)期待(dai)與(yu)同(tong)(tong)(tong)濟(ji)醫(yi)(yi)(yi)院(yuan)(yuan)(yuan)(yuan)(yuan)攜手,逐步構(gou)建(jian)起一個運轉高(gao)效、充滿活力的(de)(de)(de)產學(xue)研(yan)(yan)協(xie)同(tong)(tong)(tong)創(chuang)(chuang)新(xin)體(ti)系,共(gong)同(tong)(tong)(tong)打(da)造跨地域(yu)(yu)、跨領域(yu)(yu)協(xie)同(tong)(tong)(tong)創(chuang)(chuang)新(xin)高(gao)質量發展的(de)(de)(de)...






服務能力


